DNLI insider trading
NasdaqGS HealthcareDenali Therapeutics Inc.: insider trade history from SEC Form 4 filings.
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Company website: www.denalitherapeutics.com
DNLI insider activity at a glance
FilingIQ tracks 759 insider transactions for DNLI in filings since Dec 12, 2017. The most recent transaction is dated Sep 4, 2026.
Across the full history, 1 open-market purchases
and 520 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on DNLI insider trades is 53.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest DNLI Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for DNLI?
- FilingIQ tracks 759 Form 4 insider transactions for DNLI (Denali Therapeutics Inc.), covering filings from Dec 12, 2017 onwards. 6 of those are dated within the last 90 days.
- Are DNLI insiders net buyers or net sellers?
- Across the full Form 4 history for DNLI, 1 transactions (0%) were open-market purchases and 520 (69%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does DNLI insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is DNLI in?
- Denali Therapeutics Inc. (DNLI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.43B.
Methodology & sources
Every DNLI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.